GSK and Zhifei have revised and extended their strategic vaccine collaboration in China. The Shingrix agreement is extended to 2034, with Zhifei gaining exclusive rights to import, distribute, and co-promote the vaccine in mainland China. The deal's potential value to GSK is £2.3bn over 2024-2029, though previously contracted minimum purchase levels no longer apply.Zhifei also agrees to explore a potential 10-year collaboration on GSK's RSV vaccine, Arexvy, in mainland China, subject to regulatory approval. This partnership aims to leverage Zhifei's extensive network of over 30,000 vaccination points to improve access to innovative adult vaccines in China.The collaboration targets a market of more than 500 million people in China, including 570 million over-50s by 2030 for Shingrix, and 297 million over-60s for potential RSV vaccination. This revised agreement addresses near-term macro environment challenges while aiming for long-term growth in China's vaccine market.

GSK and Zhifei have revised and extended their strategic vaccine collaboration in China. The Shingrix agreement is extended to 2034, with Zhifei gaining exclusive rights to import, distribute, and co-promote the vaccine in mainland China. The deal's potential value to GSK is £2.3bn over 2024-2029, though previously contracted minimum purchase levels no longer apply.Zhifei also agrees to explore a potential 10-year collaboration on GSK's RSV vaccine, Arexvy, in mainland China, subject to regulatory approval. This partnership aims to leverage Zhifei's extensive network of over 30,000 vaccination points to improve access to innovative adult vaccines in China.The collaboration targets a market of more than 500 million people in China, including 570 million over-50s by 2030 for Shingrix, and 297 million over-60s for potential RSV vaccination. This revised agreement addresses near-term macro environment challenges while aiming for long-term growth in China's vaccine market.